Oruka Therapeutics
ORKA
19 hedge funds and large institutions have $41.7M invested in Oruka Therapeutics in 2015 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.
13,958% more capital inflows, than outflows
Capital inflows: $31.7M | Capital outflows: $226K
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
54.29% more ownership
Funds ownership: 4.48% → 58.77% (+54%)
36% more funds holding
Funds holding: 14 → 19 (+5)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VHCP Management
New York
|
+$9.38M |
| 2 |
NEA Management Company
Timonium,
Maryland
|
+$8.89M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$7.41M |
| 4 |
RA Capital Management
Boston,
Massachusetts
|
+$4.94M |
| 5 |
DAFNA Capital Management
Los Angeles,
California
|
+$494K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$112K |
| 2 |
Virtu KCG Holdings
New York
|
-$63K |
| 3 |
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$30.2K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$11.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$6.57K |
ORKA Hedge Fund Activity: Q2 2015 in Review
19 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2015, worth a combined $41.7M — up 5,422% from $756K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ORKA positions and 4 closed out — a net gain of 5 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was VHCP Management, opening a new position worth an estimated $9.38M. The largest seller was Sabby Management, exiting entirely with an estimated $112K sold.
- 19 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2015, up from 14 in Q1 2015.
- Funds reported $41.7M of Oruka Therapeutics stock for Q2 2015, up 5,422% quarter-over-quarter.
- 9 funds opened new Oruka Therapeutics positions in Q2 2015 and 4 closed out, a net change of +5 holders.
- The largest Oruka Therapeutics buyer in Q2 2015 was VHCP Management, an estimated $9.38M added.
- The largest Oruka Therapeutics seller in Q2 2015 was Sabby Management, an estimated $112K sold.
Based on aggregated 13F filings for Q2 2015.